Bionano Genomics, Inc. (USD) Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles. The Saphyr platform includes the Saphyr instrument, a device capable of imaging single molecules; the Saphyr Chip, a disposable component equipped with nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide essential reagents and protocols for extracting and tagging ultra-high molecular weight DNA. Furthermore, Bionano Genomics supplies Saphyr and Bionano compute servers to support its analytical operations. It also offers NxClinical, a single software system designed for the analysis and interpretation of genomic variants identified through microarray and next-generation sequencing data, serving both cytogenetics and molecular genetics applications. In addition to its product line, Bionano Genomics delivers a variety of specialized testing and laboratory services. These include: FirstStepDx PLUS: A chromosomal microarray service used to identify underlying genetic causes in individuals with autism spectrum disorder, developmental delay, and intellectual disability. Fragile X syndrome (FXS) testing services: Comprehensive diagnostic testing for FXS. NextStepDx PLUS: An exome sequencing test aimed at detecting genetic variants associated with childhood developmental disorders. EpiPanelDx PLUS: A genetic testing panel for patients experiencing seizures, infantile spasms, encephalopathy, or febrile seizures. PGx test: A pharmacogenomics test that identifies over 60 alleles across 11 genes relevant to drug response. Bionano Genomics was founded in 2003 and operates from its corporate headquarters in San Diego, California.

Bionano Genomics, Inc. (USD) Active

9540 Towne Centre Drive, San Diego, CA, US, 92121

Stock Price USD

Price Change

Last Dividend USD

B-

Latest Rating

BNGO's stock peer is AIM (AIM ImmunoTech Inc.)

BNGO's stock peer is BNBX (BNB Plus Corp.)

BNGO's stock peer is KTTA (Pasithea Therapeutics Corp.)

BNGO's stock peer is MYNZ (Mainz Biomed B.V.)

BNGO's stock peer is NDRA (ENDRA Life Sciences Inc.)

BNGO's stock peer is POAI (Predictive Oncology Inc.)

BNGO's stock peer is QNRX (Quoin Pharmaceuticals, Ltd.)

BNGO's stock peer is VYNE (VYNE Therapeutics Inc.)

BNGO's stock peer is XTLB (XTL Biopharmaceuticals Ltd.)

Healthcare Medical - Diagnostics & Research

Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles. The Saphyr platform includes the Saphyr instrument, a device capable of imaging single molecules; the Saphyr Chip, a disposable component equipped with nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide essential reagents and protocols for extracting and tagging ultra-high molecular weight DNA. Furthermore, Bionano Genomics supplies Saphyr and Bionano compute servers to support its analytical operations. It also offers NxClinical, a single software system designed for the analysis and interpretation of genomic variants identified through microarray and next-generation sequencing data, serving both cytogenetics and molecular genetics applications. In addition to its product line, Bionano Genomics delivers a variety of specialized testing and laboratory services. These include: FirstStepDx PLUS: A chromosomal microarray service used to identify underlying genetic causes in individuals with autism spectrum disorder, developmental delay, and intellectual disability. Fragile X syndrome (FXS) testing services: Comprehensive diagnostic testing for FXS. NextStepDx PLUS: An exome sequencing test aimed at detecting genetic variants associated with childhood developmental disorders. EpiPanelDx PLUS: A genetic testing panel for patients experiencing seizures, infantile spasms, encephalopathy, or febrile seizures. PGx test: A pharmacogenomics test that identifies over 60 alleles across 11 genes relevant to drug response. Bionano Genomics was founded in 2003 and operates from its corporate headquarters in San Diego, California.

100%

Dcf Rating

20%

Return On Equity

20%

Return On Assets

40%

Debt To Equity

20%

Price To Earnings

100%

Price To Book

Income Statement

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
Dividend Data Not Exist

Recent News

Bionano Announces Hiring of Chief Scientific Officer

SAN DIEGO, June 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a leader in genome analysis solutions, today announced the appointment of Alex Hastie, Ph.D., as its Chief Scientific Officer (CSO), effective July 20, 2026. In this role, Dr. Hastie will lead the company's global scientific strategy, innovation roadmap, and research initiatives, advancing Bionano's mission to expand the research application of its genome analysis technologies and to develop a clinical applications strategy.

2026-06-24 08:30:00

Bionano Announces 67% Year-Over-Year Growth in Studies Featuring Optical Genome Mapping at ESHG 2026, Reflecting Expanding Global Adoption

SAN DIEGO, June 18, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that studies featuring optical genome mapping (OGM) at the 2026 European Society of Human Genetics (ESHG) conference grew substantially compared to the conference in 2025, consistent with expanding global adoption of OGM. Key highlights from studies of OGM presented at ESHG 2026: 35 studies featured OGM — a 67% increase over the 21 studies reported at ESHG 2025.

2026-06-18 08:00:00

Bionano Announces Multiple Publications in 2026 Describing Unique Utility of OGM in Studies of Reproductive Health and Prenatal Genetic Disorders

SAN DIEGO, June 11, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that to date in 2026, a total of 13 studies analyzing 730 samples were published with key findings that demonstrate the utility of optical genome mapping (OGM) for the detection and characterization of structural variants (SVs) in studies of reproductive health and prenatal genetic disorders. Reproductive disorders including infertility and recurrent pregnancy loss are highly prevalent and very often carry a genetic component.

2026-06-11 08:00:00

Bionano Announces Full Retirement of Outstanding Senior Secured Convertible Debentures

SAN DIEGO, May 28, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has fully retired and cancelled all outstanding Senior Secured Convertible Debentures (the "Debentures"). The Company used cash on hand to retire the Debentures, which were originally issued in May 2024 in the aggregate face value of $20,000,000.

2026-05-28 08:00:00

Bionano Announces Largest OGM Study of T-Cell Acute Lymphoblastic Leukemia

SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced publication of a peer-reviewed study in Modern Pathology showing that optical genome mapping (OGM) detected genomic abnormalities in 97.8% of T-cell acute lymphoblastic leukemia (T-ALL) cases — nearly double the 55% detection rate achieved by conventional cytogenetic analysis. Conducted by researchers at The University of Texas MD Anderson Cancer Center and Johns Hopkins University School of Medicine and representing one of the most comprehensive genomic analyses of T-ALL to date, the study underscores OGM's potential to transform how this aggressive blood cancer is studied and understood.

2026-05-26 08:00:00

Bionano Reports First Quarter 2026 Results and Provides a Business Update

SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the first quarter ended March 31, 2026. "The Bionano business is healthy, with first quarter results reflecting the continued engagement of our installed base and positive utilization trends across our optical genome mapping (OGM) and VIA software user community," commented Al Luderer, Ph.D.

2026-05-13 16:05:00

Bionano Announces Leadership Transition

SAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Al Luderer, Ph.D., chairman of Bionano's Board of Directors, has been appointed interim president and chief executive officer, effective May 5, 2026. Dr. Luderer will continue to serve as chairman, and director Chris Twomey will serve as Lead Independent Director. He succeeds Erik Holmlin, PhD, who is staying on as an advisor. The company anticipates a seamless transition without business disruption.

2026-05-06 16:30:00

Bionano Announces a 56% Increase in Publications Describing the Utility of OGM in Rare Diseases in Q1 2026 vs Q1 2025

Overall, studies show: OGM Can Resolve Previously Unresolved Rare Disease Cases OGM Can Serve as a Gold Standard Technique for Characterization of SVs OGM Can Complement Sequencing for Better SV Sensitivity and Genomic Insights OGM Can Identify Actionable Disrupted Genes Across Rare Diseases SAN DIEGO, May 05, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) reported that 28 publications describing the utility of optical genome mapping (OGM) for analysis of rare diseases were released in Q1 2026, representing an approximately 56% increase over last year. The total number of samples analyzed, 78, represents a 225% increase compared to the number analyzed in studies published in Q1 2025 (24).

2026-05-05 08:00:00

Bionano to Report First Quarter 2026 Financial Results and Host a Conference Call Webcast on May 13, 2026

SAN DIEGO, April 29, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 13, 2026, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2026 and to highlight recent corporate progress.

2026-04-29 16:05:00

Bionano Announces Publication from Johns Hopkins and MD Anderson Showing that OGM can Outperform Traditional Methods in Analysis of Multiple Myeloma

SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced the publication of a study in the American Journal of Hematology demonstrating that optical genome mapping (OGM) can significantly outperform traditional analytical methods for detection of structural variations and chromosomal abnormalities in multiple myeloma (MM), a complex hematologic malignancy known for its low success rate when analyzed by traditional cytogenetic methods. The multicenter study, led by scientists from Johns Hopkins University School of Medicine and The University of Texas MD Anderson Cancer Center, found that OGM performed on real-world clinical research samples was concordant with traditional methods, had a higher overall success rate for finding pathogenic or likely pathogenic abnormalities, and yielded a result for a substantial fraction of samples that failed to reveal an answer using traditional workflows, overcoming limitations of MM analysis by techniques such as fluorescence in situ hybridization (FISH), karyotyping, and next-generation sequencing (NGS).

2026-04-02 08:00:00

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions